Aberdeen Group’s Edgewise Therapeutics EWTX Stock Holding History

Aberdeen Group’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.8M	Sell	413,373 -234,553	-36%	-$10M	0.02%	517
2026 Q2	$26.3M	Sell	647,926 -178,133	-22%	-$6.14M	0.04%	369
2026 Q1	$26M	Buy	826,059 +4,119	+0.5%	+$119K	0.04%	341
2025 Q4	$20.4M	Buy	821,940 +202,062	+33%	+$4.06M	0.03%	425
2025 Q3	$10.1M	Buy	619,878 +176,559	+40%	+$2.5M	0.02%	603
2025 Q2	$5.81M	Buy	443,319 +130,294	+42%	+$1.88M	0.01%	684
2025 Q1	$6.89M	Buy	313,025 +134,982	+76%	+$3.54M	0.01%	641
2024 Q4	$4.75M	Sell	178,043 -78,602	-31%	-$2.5M	0.01%	656
2024 Q3	$6.85M	Buy	+256,645	New	+$5.11M	0.01%	596
2024 Q1	–	Sell	-150,418	Closed	-$1.65M	–	957
2023 Q4	$1.65M	Buy	+150,418	New	+$1.06M	﹤0.01%	788

Other funds holding EWTX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return

Aberdeen Group's EWTX Position: Q3 2026 in Review

Aberdeen Group reduced its Edgewise Therapeutics (EWTX) stake by 36% in Q3 2026, selling an estimated $10M and leaving 413,373 shares worth $16.8M. The position accounts for 0.02% of the portfolio, ranked #517.

Aberdeen Group first reported a position in EWTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $26.3M in Q2 2026. 70 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

Aberdeen Group held 413,373 shares of Edgewise Therapeutics worth $16.8M as of Q3 2026.
Aberdeen Group sold 234,553 Edgewise Therapeutics shares in Q3 2026, an estimated $10M.
Edgewise Therapeutics made up 0.02% of Aberdeen Group's portfolio in Q3 2026, its #517 holding.
Aberdeen Group first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 10 quarters since.
Aberdeen Group's Edgewise Therapeutics position peaked at $26.3M in Q2 2026.
70 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.